Prostate cancer, notorious for its variable clinical outcomes, poses a significant threat largely due to its capacity for metastasis and therapy resistance. A critical factor enabling this aggressive phenotype is metabolic adaptation, particularly glycolysis, which cancer cells hijack even in oxygen-rich environments—a phenomenon famously known as the Warburg effect. Despite the extensive research into cancer metabolism, the precise molecular crosstalk that sustains this aberrant metabolic state alongside cancer progression remained elusive. The new study meticulously deciphers a hitherto uncharted regulatory circuit involving RNA-binding proteins, circular RNAs, microRNAs, and signaling GTPases.

Central to this feedback loop is ESRP1 (Epithelial Splicing Regulatory Protein 1), a splicing factor that orchestrates alternative RNA processing events pivotal in cancer biology. ESRP1 was found to significantly influence the generation of circPHGDH, a circular RNA derived from the PHGDH gene, which intersects oncogenic signaling and metabolism. Unlike linear RNAs, circular RNAs form covalently closed loops, endowing them with enhanced stability and unique regulatory capabilities, including acting as molecular sponges for microRNAs.

circPHGDH emerges as a crucial molecular scaffold in this network by sequestering miR-149, a microRNA that typically functions as a tumor suppressor by downregulating target oncogenes. The sequestration of miR-149 by circPHGDH diminishes its availability, resulting in the derepression of RAP1B, a Ras-related small GTPase implicated in cell proliferation, migration, and invasion. RAP1B, in turn, amplifies signals that upregulate ESRP1, closing the feedback loop that continuously enhances both malignant behaviors and glycolytic metabolism.

This mechanistic insight was substantiated through a series of intricate experiments employing prostate cancer cell lines and patient-derived samples. Molecular assays demonstrated that upregulation of ESRP1 increases circPHGDH levels, which then captures miR-149, leading to elevated RAP1B expression. Knockdown studies disrupting any component of this axis effectively curtailed glycolysis rates, cell proliferation, and invasive capabilities, underscoring the pathological relevance of this feedback loop.

Moreover, metabolic flux analyses revealed that this feedback loop promotes aerobic glycolysis, providing prostate cancer cells with a rapid supply of ATP and biosynthetic intermediates. This metabolic pivot is essential for supporting the energy-intensive processes of cell motility and growth, facilitating metastasis and resistance to conventional therapies. The study’s findings position the ESRP1/circPHGDH/miR-149/RAP1B axis as a critical metabolic and oncogenic hub within prostate cancer pathophysiology.

The research also delves into the therapeutic potential of disrupting this loop. By selectively targeting circPHGDH or modulating miR-149 levels, there is a promising opportunity to reinstate tumor suppressive pathways and impair the metabolic flexibility of cancer cells. Such strategies could pave the way for combination therapies aimed at crippling cancer metabolism and halting tumor progression.

This discovery is particularly exciting because it highlights the multifaceted roles of non-coding RNAs in cancer biology beyond mere genetic expression. The circular RNA circPHGDH exemplifies how non-coding transcripts can intricately modulate microRNA activity and thereby influence signaling cascades that underpin oncogenesis. This paradigm shift extends the horizon of potential molecular targets that were previously underestimated or overlooked.

Additionally, the role of ESRP1 as a splicing regulator adds another layer of complexity. Its involvement in regulating circular RNA production connects alternative splicing with metabolic reprogramming, revealing how post-transcriptional modifications can drive cancer cell behavior. This nexus between RNA processing and metabolic control represents fertile ground for future research and drug development.

The involvement of RAP1B, a member of the Ras superfamily, in this feedback network reaffirms the significance of small GTPases in cancer metastasis. RAP1B’s established functions in cytoskeletal dynamics and integrin-mediated adhesion make it an attractive target for metastasis intervention. The feedback loop tightly couples RAP1B expression to upstream RNA regulators, suggesting new avenues for disrupting metastatic signaling pathways at multiple regulatory junctions.

Importantly, the clinical relevance of this molecular circuitry was validated in prostate cancer tissues where elevated ESRP1, circPHGDH, and RAP1B correlated with aggressive disease phenotypes and poor prognosis. This translational aspect reinforces the potential for biomarker development based on components of the feedback loop, which might assist clinicians in risk stratification and personalized treatment planning.

Furthermore, the insights into metabolic remodeling mediated by this feedback loop resonate with the evolving landscape of cancer metabolism research. Targeting glycolysis has been an attractive yet challenging therapeutic strategy due to the metabolic plasticity of cancer cells. Understanding the upstream regulators such as this RNA-centric axis opens new doors to finely tune metabolic interventions with greater specificity and efficacy.

In sum, the elucidation of the ESRP1/circPHGDH/miR-149/RAP1B positive feedback loop not only advances our understanding of prostate cancer biology but also offers a compelling framework for therapeutic innovation. By bridging molecular RNA biology, metabolic adaptation, and oncogenic signaling, this study provides a holistic view of tumor progression mechanisms, charting a promising path toward more effective cancer treatments.

As the field moves forward, exploring the broader applicability of such feedback loops across different cancer types and understanding their interactions with other oncogenic networks will be paramount. The integration of high-throughput molecular profiling and functional genomics will undoubtedly accelerate the discovery of similar regulatory circuits, propelling cancer research into an era of precision medicine that targets the cancer cell’s nutri-oncogenic dependencies.

This landmark study published in Experimental & Molecular Medicine encapsulates the potential of combining RNA biology and metabolism to unravel the enigmatic nature of cancer malignancy. By decoding the sophisticated feedback loop at the heart of prostate cancer’s metabolic and proliferative prowess, researchers have illuminated a beacon of hope that might soon be harnessed to thwart this devastating disease.

Subject of Research: Molecular mechanisms underpinning malignant behaviors and metabolic reprogramming in prostate cancer cells.

Article Title: A ESRP1/circPHGDH/miR-149/RAP1B positive feedback loop promotes the malignant behaviors and glycolysis of prostate cancer cell.

Article References:
Wang, X., Yu, L., Qian, X. et al. A ESRP1/circPHGDH/miR-149/RAP1B positive feedback loop promotes the malignant behaviors and glycolysis of prostate cancer cell. Exp Mol Med (2026). https://doi.org/10.1038/s12276-026-01646-x

Image Credits: AI Generated

DOI: 10.1038/s12276-026-01646-x

At the heart of this research lies the tumor suppressor protein p53, often hailed as the “guardian of the genome” due to its critical role in maintaining genomic stability and preventing malignant transformation. Although extensively studied in the context of many cancers, the exploration of p53 isoforms – variant forms of the protein arising through alternative splicing, transcriptional initiation, and post-translational modifications – has remained relatively underappreciated until now. This study breaks new ground by characterizing these isoforms in uveal melanoma, a malignancy notorious for its poor prognosis and resistance to conventional therapies.

Uveal melanoma represents the most common primary intraocular malignancy in adults and is distinct from cutaneous melanoma both biologically and clinically. Here, the researchers harnessed a combination of advanced molecular biology techniques, including isoform-specific RNA sequencing and immunoblot analyses, to delineate the expression patterns of multiple p53 variants. Their work reveals that rather than functioning as a monolithic tumor suppressor, p53 operates through a network of isoforms with varied and sometimes contradictory roles in tumor suppression, apoptosis, and cellular senescence.

One of the pivotal revelations from this study is the identification of isoforms that differentially modulate transcriptional activity on canonical p53 target genes. This nuanced activity implies that the traditional view of p53-induced apoptosis and cell cycle arrest must be expanded to accommodate isoform-specific functionality. For instance, some isoforms exhibit a diminished capacity to activate apoptotic pathways while others actively suppress senescence-inducing genes, suggesting a complex interplay that could facilitate tumor cell adaptability and survival.

Moreover, the data underscore an unexpected heterogeneity in p53 isoform expression among different cellular subpopulations within uveal melanoma tumors. This intratumoral diversity may underpin the variable responses to DNA damage and therapeutic insults, providing a molecular basis for the notoriously heterogeneous clinical outcomes observed in patients. Understanding the distribution and regulation of these isoforms promises to unveil new biomarkers for prognosis and treatment stratification.

Intriguingly, the study also illuminates the post-translational modifications shaping isoform functionality. Phosphorylation, acetylation, and ubiquitination patterns specific to certain isoforms were identified, hinting at additional layers of regulation that fine-tune tumor suppressor activity in real time. These modifications potentially alter protein stability, subcellular localization, and interactions with cofactors, contributing further to functional heterogeneity.

The authors explore how this isoform diversity impacts cellular stress responses, particularly in relation to DNA repair mechanisms and oxidative stress pathways. Certain isoforms appear to bolster repair processes, enhancing cell survival, while others favor programmed cell death mechanisms. These dichotomous effects highlight an intrinsic balance within the tumor microenvironment’s regulatory circuitry, a balance that can dictate tumor progression or regression.

Cutting-edge bioinformatics analyses provided critical insights into the evolutionary conservation of these isoforms, arguing for their physiological relevance across species and tissues. This evolutionary perspective implies that the multiplicity of p53 isoforms has been maintained to fulfill versatile and context-dependent regulatory roles – a testimony to the complexity of cellular homeostasis.

Furthermore, the study paves the way for tailored therapeutic interventions that can selectively target detrimental isoforms or boost protective ones. Pharmacological modulation of p53 isoforms could circumvent the limitations of therapies solely focused on the canonical p53 pathway and improve clinical outcomes. In the context of uveal melanoma, such stratagems are particularly urgent given the limited efficacy of existing treatments once metastatic disease arises.

In addition to pharmacological prospects, the researchers propose that isoform profiling might be integrated into diagnostic workflows to better predict tumor behavior and patient prognosis. By refining molecular subtyping based on p53 isoform expression patterns, clinicians could eventually personalize surveillance and therapeutic regimens with heightened precision. This represents a paradigm shift in the clinical management of uveal melanoma.

The interplay of p53 isoforms with other oncogenic pathways was also scrutinized, revealing crosstalk that can either amplify or mitigate tumorigenic signals. This network-level understanding stresses the necessity of systems biology approaches to unravel how p53 functions within the broader oncogenic context. Such holistic perspectives may be invaluable for designing combination therapies.

Finally, the research highlights the challenges ahead in the study of p53 isoforms, including the development of robust isoform-specific antibodies and tools for precise in vivo modeling. Overcoming these technical barriers will be critical to translating bench discoveries into clinical applications, heralding a new era in the fight against uveal melanoma and potentially other malignancies.

In conclusion, this comprehensive and technically sophisticated investigation reveals that the p53 tumor suppressor is far from a singular entity but rather a dynamic ensemble of isoforms that orchestrate diverse cellular fates. This insight holds transformative potential for cancer biology, providing new avenues for diagnosis, prognosis, and targeted therapy, and underscores the critical need to consider molecular heterogeneity in the design of future cancer interventions.

Subject of Research: The study investigates the heterogeneous functionality of p53 isoforms as tumor suppressors in uveal melanoma, elucidating their distinct molecular roles and regulatory mechanisms.

Article Title: Exploring p53 isoforms: unraveling heterogeneous p53 tumor suppressor functionality in uveal melanoma.

Article References: Bartolomei, L., Ciribilli, Y., Brugnara, S. et al. Exploring p53 isoforms: unraveling heterogeneous p53 tumor suppressor functionality in uveal melanoma. Cell Death Discov. (2025). https://doi.org/10.1038/s41420-025-02891-1

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02891-1